《瑞银窝轮》港交所仍受惠中概上市 看好参考购15876
7月恒指曾上试27000点，不过无功而还，基乎没有升跌，但月内波幅超过2000点。拖累大市比较多的要数友邦(1299)和汇丰(0005)两者合共拖低大市约140点，不过腾讯(0700)力撑大市，单只股份贡献恒指约220点升幅，而港交所(0388)走势亦不错，带动恒指140点左右的升幅。
事实上，继网易(9999)以及京东(9618)之後，更多具规模的中概股陆续放风来香港上市，亦令市场更憧憬进一步带动港股交投。早前蚂蚁集团指会AH上市，港交所当日就升34港元，同日一众中概股亦急升，反映市场对类似的消息仍然非常受落，如投资者认为港交所能持续受惠，可留意港交所认购15876，行使价400.2港元，20年12月到期，有效杠杆约6.4倍。
另外腾讯在7月累讯升8%，相对其他ATMX股份最少10%的累积升幅，明显较为落後，所以每当腾讯股价下跌时，资金亦非常积极留意共认购证选择。如投资者看好腾讯，可留意腾讯控股认购16232，行使价640.5港元，20年12月到期，有效杠杆约6.8倍。
此外，新型肺炎疫情仍困扰全球，各地政府亦在封城封关以及逐步重启经济活动之间徘徊，虽然内地新型肺炎疫情早已受控，不过疫情推动出来的部份新经济概念仍得以延续，以平安好医生(1833)以为例，虽然7月上旬没有什麽令人惊喜的表现，不过仍有大行看好其受惠政策，以及陆续推出的新项目将有利股价，上周中开始平安好医生得到支持而上升，创高位134.2港元。如投资者看好平医，可留意平安好医生认购26840，行使价148港元，20年10月到期，有效杠杆约5.7倍。
更多窝轮牛熊资讯：瑞银证网站: www.ubs.com/hkwarrants
窝证教学及市况焦点短片:
https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber
卓素华
董事
瑞银亚洲股票衍生产品销售部
本产品并无抵押品。 如发行人无力偿债或违约,投资者可能无法收回部份或全部应收款项。笔者为UBS AG的代表(作为证监会持牌人)，并未持有相关上市公司的任何财务权益。本资料由瑞银刊发，其并不构成买卖建议、邀请、要约或游说。结构性产品价格可急升或急跌，投资者可能会蒙受全盘损失。过往表现并不反映将来表现。牛熊证备强制赎回机制而可能被提早终止，届时 (i) N类牛熊证投资者将不获发任何金额;而(ii) R类牛熊证之剩余价值可能为零。投资前应了解有关风险，并谘询专业顾问及查阅有关上市文件。UBS Securities Hong Kong Limited为结构性产品之流通量提供者，亦可能是唯一报价者或市场参与者。(C) UBS 2020。版权所有。~
重要声明:
以上资讯由第三方提供，AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告，不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料，本公司亦不负品质保证之责任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
